{'fraction_non_alphanumeric': 0.029940119760479042, 'fraction_numerical': 0.004790419161676647, 'mean_word_length': 4.648648648648648, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Duloxetin--a new tool in pharmacotherapy of urinary incontinence in women].

Urinary incontinence (UI) is represented clinically by stress, urgent, mixed forms. Until recently, effective pharmacological treatment of stress UI was absent. Now, attempts are made to try duloxetin to raise efficacy of conservative treatment and quality of life in patients with stress and mixed UI. A large, double blind, placebo-controlled, randomized phase II trial provided data on efficacy of duloxetin in the treatment of stress and mixed UI in women. Duloxetin led to a decrease in the number of incontinence episodes, a rise in quality of life. It was rather effective in severe UI. Phase III trial of duloxetin in a dose 80 mg/day reduced the number of incontinence episodes by 50% in most of the patients and in some of them cured the patients.